oa The Dabigatran debate

References

1. Kaba RA, Camm AJ, Williams TM, Sharma R. Managing atrial fibrillation in the global community: The European perspective. Glob Cardiol Sci Pract. 2013; 2013:2:173–184. doi:10.5339/gcsp.2013.24 .
   [Google Scholar]
2. Al-Kindi S. Lack of reversibility for NOACs. Glob Cardiol Sci Pract. 2014; 2014:1:1. doi:10.5339/gcsp.2014.1 .
   [Google Scholar]
3. Kaba RA, Ahmed O, Cannie D. Response to “Lack of reversibility for NOACs.”. Glob Cardiol Sci Pract. 2014; 2014:1:2. doi:10.5339/gcsp.2014.2 .
   [Google Scholar]
4. Boehringer Ingelheim. Dabigatran etexilate recommended for approval in atrial fibrillation for stroke prevention in Europe http://www.boehringer-ingelheim.ca/en/news/press_releases/2011/15_april_2011.html .
5. Charlton B, Redberg R. The trouble with dabigatran. BMJ. 2014 Jul 23; 349::g4681. doi: 10.1136/bmj.g4681 .
   [Google Scholar]
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:12:1139–1151. doi:10.1056/NEJMoa0905561 .
   [Google Scholar]
7. Cohen D. Concerns over data in key dabigatran trial. BMJ. 2014 Jul 23; 349::g4747. doi: 10.1136/bmj.g4747 .
   [Google Scholar]
8. DiNicolantonio JJ. Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. Expert Opin Pharmacother. 2012; 13:8:1101–1111. doi: 10.1517/14656566.2012.671809 .
   [Google Scholar]
9. Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ. 2014 Jul 23; 349::g4517. doi: 10.1136/bmj.g4517 .
   [Google Scholar]
10. Boehringer Ingelheim. (2013 September). Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data.
11. McConeghy K, Bress A, Wing C. Reports of bleeding-related fatalities with dabigatran and warfarin: An analysis using the food and drug administration adverse events reporting system. J Am Coll Cardiol. 2013; 61:10_S. doi:10.1016/S0735-1097(13)60319-8 .
    [Google Scholar]
12. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013; 368:14:1272–1274. doi:10.1056/NEJMp1302834 .
    [Google Scholar]
13. Bloomberg News. (2013 11-December). Boehringer to Pay $931,000 Fine Over Lost Pradaxa Files.
14. Cohen D. Dabigatran: How the drug company withheld important analyses. BMJ. 2014 Jul 23; 349::g4670. doi:10.1136/bmj.g4670 .
    [Google Scholar]
15. Boehringer Ingelheim. (2014 25-July). Pradaxa^® (dabigatran etexilate): Response to the recent media articles.
16. Boehringer Ingelheim. (2014 28-May). Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa^® (dabigatran etexilate) litigation.
17. Boehringer Ingheim. (2014 14-August). Dabigatran and the monitoring of plasma levels in patients.
18. Reuters. (2014 25-April). UPDATE 1-Boehringer 2013 profit up on Pradaxa sales, cost cuts.